

P R E S S R E L E A S E

FOR IMMEDIATE RELEASE
February 7th, 2024

CONTACT: Farah El-zarkout
Business Development Manager
farah.elzarkout@mediphage.ca

Mediphage Bioceuticals, Inc. Closes Seed Round of Financing

Toronto, Ontario – Mediphage Bioceuticals, a biotechnology company driving the next generation of genetic medicines, announced today the closing of its Seed financing round.

Mediphage is pleased to announce it has successfully closed its seed funding round. A mix of early Mediphage supporters, including CCRM Enterprises Holdings Ltd, Riverine Ventures, and Bio Med Ventures, as well as new investors participated in the syndicate.

The investment will drive the company's internal therapeutic and manufacturing programs, while enabling Mediphage to continue supporting its growing number of external collaborations with pharmaceutical and biotechnology companies, CDMOs, and national research organizations.

Mediphage's novel ministring DNATM (msDNATM) platform is a novel, linear, covalently closed, high-fidelity, and backbone-free DNA minivector produced using a proprietary and scalable *E. coli*-based manufacturing process. msDNATM is being used in a variety of therapeutic applications, including non-viral gene therapy, *ex vivo* cell therapy, and *in vivo* gene editing. msDNATM has also been successfully tested as a starting material for the production of viral vectors like rAAVs and lentivirals, as well as mRNA therapeutics, and DNA vaccines.

"We are very grateful for the support and vision from our existing and new investors in these challenging times for early stage biotech companies. We are excited about our multiple collaborations across various applications as the insights and data we are generating are already indicative of the potential transformative power that msDNATM will have in gene therapy," says Alvaro Amorrortu, President and CEO of Mediphage.

"We're passionate about championing Canadian solutions that are making a significant impact in the genetic medicine space, and believe that msDNATM will play a critical role in maximizing the potency and quality of Advanced Therapy Medicinal Products," says Cynthia Lavoie, President and Chief Investment Officer of CCRM Enterprises Inc.

About Mediphage

Mediphage has developed a novel, linear, covalently closed, high-fidelity, and backbone-free DNA minivector, ministring DNATM (msDNATM), that is produced using a proprietary and scalable *E. coli*-based manufacturing process. msDNATM can be used across a range of genetic medicine applications, including non-viral gene therapy, *ex vivo* cell therapy, and *in vivo* gene editing. msDNATM is also a starting material for the production of viral vectors like rAAV and lentiviral vectors, mRNA therapeutics, and DNA vaccines. Mediphage is currently engaged in collaborations with the world's largest pharmaceutical and biotechnology companies to further develop the above applications.